Multiple Myeloma is a form of cancer formed by malignant plasma
cells. Malignant tumors are formed from highly unstable abnormal
cells travelling via the blood stream, circulatory system, and
lymphatic system. The plasma cells become cancerous and vigorously
proliferative, producing tumor called plasmacytoma that prevents the
bone marrow from producing healthy blood cells and immunoglobulins.
The formation and proliferation of myeloma cells result in fewer
leukocyte, erythrocyte, and platelet cell formation causing a damaged
immune system. Gastrointestinal problems, enlarged organs, kidney
damage, rapid weight loss, bone pain, and fever are some of the
common symptoms of multiple myeloma. Multiple myeloma is considered
to be the third most common blood cancer followed by lymphoma and
leukemia.
Download
PDF Brochure of This Business Report @
https://www.coherentmarketinsights.com/insight/request-pdf/839
Introduction of monoclonal antibodies with safety profile to fight
myeloma cells is expected to drive the multiple myeloma drugs market
The increasing microRNA therapeutics, nanomedicine platform
emergence, and constant introduction of effective and safe
therapeutics drives the growth of multiple myeloma drugs market. The
drugs market is expected to gain momentum with the addition of
monoclonal antibodies and Histone Deacetylase (HDAC) inhibitors to
the current therapeutics array. The biologic therapy of monoclonal
antibodies including DARZALEX and EMPLICITI are largely preferred by
the physicians owing to the established clinical profile. The growing
prevalence of the disorder with the surging elderly population, the
inefficiency of the current medication augments to invest in research
and development, thereby driving the global market in the forecast
period. Additionally, the supportive treatment demand for
restoration procedures including point of care technologies, approved
safety profile and efficiency of monoclonal antibodies is expected to
broaden the drug treatment received by the patients.
Novel targeted therapy segment is expected to fuel the multiple
myeloma drugs market
The global multiple myeloma drugs market is segmented on the basis of
technology, diagnosis, surgery, end user and geography.
On the basis of drug type, the global multiple myeloma drugs
market is segmented into:
• Immunomodulating agents
• Proteasome inhibitors
• Histone Deacetylase (HDAC) inhibitors
• Steroids (Corticosteroids)
• Monoclonal antibodies
On the basis of distribution channel, the global multiple myeloma
drugs market is segmented into:
• Hospital Pharmacy
• Retail Pharmacy
• ePharmacies
Launching drugs due to high unmet medical needs of patients is a
strategy adopted by key players
Key players operating the global multiple myeloma drugs market
include Novartis, Johnson & Johnson, Elgene, Takeda
Pharmaceuticals, and Amgen. The strategies adopted by the key players
include advances in research activities, the launch of novel
therapies specific for effective treatment due to unmet medical needs
increase the competition among vendors. Other leading vendors include
Acceleron Pharma, Bristol-Meyer Squibb, Sanofi, GlaxoSmithKline, and
Merck.
Browse
Full Exclusive Research Report at
https://www.coherentmarketinsights.com/ongoing-insight/multiple-myeloma-drugs-market-839
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
No comments:
Post a Comment